Fierce Pharma
MARCH 4, 2024
When Pfizer completed its $43 billion buyout of Seagen in December | Less than three months after completing its $43 billion acquisition of Seagen, Pfizer has confirmed a report that it is shutting down construction of a $350 million manufacturing facility in Everett, Washington. The decision will affect 120 employees working on the initial setup of the site, the company said.
pharmaphorum
MARCH 4, 2024
Inhaled cannabinoids have been shown to perform better than placebo in providing pain relief for people suffering from acute migraine in a clinical trial
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
MARCH 4, 2024
A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.” | A little more than half a year after winning a historic over-the-counter nod, Perrigo’s nonprescription birth control pill Opill is set to hit store shelves in the “coming weeks.
MedCity News
MARCH 4, 2024
Kellogg CEO Gary Pilnick recently encouraged families struggling to put food on the table to turn to cereal as their go-to dinner option. Food-as-medicine executives are none too thrilled about his comments — they argue that the remarks underscore the dire need to increase public education about affordable, healthy meal planning.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
MARCH 4, 2024
After decades of research into respiratory syncytial virus (RSV), Pfizer and GSK’s groundbreaking vaccines made waves as the first immunizations against the common respiratory illness. | After a preliminary analysis found a potentially higher risk of Guillain-Barré syndrome following RSV vaccination in older adults, GSK and Pfizer said they will conduct further safety studies.
MedCity News
MARCH 4, 2024
Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MARCH 4, 2024
Healthcare organizations will need to proactively engage the next generation of workers in order to meet demand. They can start by factoring in these trends and creating an environment that supports a healthy work-life balance, finding opportunities to prioritize flexibility, and leaving room to staff up for new and expanding care fields.
Fierce Pharma
MARCH 4, 2024
Johnson & Johnson continues to grow its oncology franchise with a new FDA approval that opens the lung cancer drug Rybrevant to treating certain newly diagnosed patients. | Johnson & Johnson continues to grow its oncology franchise with a new FDA approval that opens the lung cancer drug Rybrevant to treating certain newly diagnosed patients.
pharmaphorum
MARCH 4, 2024
The clock has started ticking in the EU on two marketing applications for AstraZeneca and Daiichi Sankyo’s TROP2-targeting antibody-drug conjugate datopotamab deruxtecan in breast and lung cancer. The EMA has validated the two parallel applications for the drug, also known as Dato-DXd, in adults with previously treated non-small cell lung cancer (NSCLC) and hormone receptor-positive, HER2-negative breast cancer.
Fierce Pharma
MARCH 4, 2024
After the U.S. | With the counteroffers, the IRA-mandated negotiations period has begun and will continue through August.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
MARCH 4, 2024
In late 2023, the Medicines and Healthcare products Regulatory Agency approved Vertex’s Casgevy, which became the inaugural clustered regularly interspaced short palindromic repeats (CRISPR)-based drug for the haematological indications beta thalassemia and sickle cell disease (SCD).
MedCity News
MARCH 4, 2024
Here are six actionable steps healthcare organizations can take to reduce their likelihood of denials and write-offs.
Pharmaceutical Commerce
MARCH 4, 2024
The latest news for pharma industry insiders.
pharmaphorum
MARCH 4, 2024
Bayer licenses European rights to BridgeBio's acoramidis, putting some big pharma muscle behind the ATTR cardiomyopathy treatment
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
MARCH 4, 2024
The EMA has validated the jointly developed TROP2-directed therapy for patients with breast or lung cancer following positive Phase III data.
PharmaTimes
MARCH 4, 2024
In the UK alone, the aggressive form of cancer affects around 52,000 men every year
European Pharmaceutical Review
MARCH 4, 2024
As a cornerstone of advanced therapeutics in modern medicine, biologics command significant attention in the search for effective treatments for human diseases. These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. 1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs.
PharmaTimes
MARCH 4, 2024
Around 900,000 people in the UK are affected by the progressive neurodegenerative disease
Pharmatutor
MARCH 4, 2024
Architect of Indian Pharmacy Education : Prof. Mahadev Lal Schroff admin Mon, 03/04/2024 - 16:44 ABOUT AUTHOR Dr. R. S. Thakur Former Secretary, Pharmacy Council of India. Email : drramsthakur@gmail.
European Pharmaceutical Review
MARCH 4, 2024
According to new data in older and heavier children treated with Novartis’ spinal muscular atrophy (SMA) gene therapy, nearly all participants in the Phase IIIb trial maintained or improved motor milestones after 52 weeks. Final data from the Phase IIIb SMART study of Zolgensma ® (onasemnogene abeparvovec) highlighted its safety and efficacy in children weighing ≥ 8.5kg to ≤ 21kg, with a mean age of 4.69 years.
Pharmaceutical Technology
MARCH 4, 2024
For Rare Disease Day, several panels organised by the FDA discussed the importance overcoming accessibility barriers during drug development.
PharmaVoice
MARCH 4, 2024
Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
MARCH 4, 2024
Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, bolstering ophthalmology and biosimilar expertise.
Scott’s Directories
MARCH 4, 2024
In the competitive world of B2B sales and marketing, bridging geographical gaps is crucial for reaching new markets and expanding business opportunities. This is especially true when targeting the medical and healthcare sectors in Manitoba. One effective tool for overcoming these barriers is the doctors directory from MD Select. This comprehensive resource not only simplifies the process of finding and connecting with key medical professionals but also enhances sales strategies by providing accu
PharmaTech
MARCH 4, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
LEVO Health
MARCH 4, 2024
Healthcare professionals (HCPs) are currently inundated with information and marketing messages. Therefore, standing out in the crowded HCP marketing space requires strategic innovation and a deep understanding of HCP needs and behaviors. Exploring effective strategies to overcome the clutter, establishing meaningful connections with each audience, and leveraging the latest trends and data-driven insights are crucial for successful HCP marketing.
PharmExec
MARCH 4, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Commerce
MARCH 4, 2024
The purchase boosts the parties’ sterile liquid manufacturing capabilities.
PharmExec
MARCH 4, 2024
In this Pharmaceutical Executive video interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics, discusses data security threats from human error to AI tech and how COVID-19 impacted data integrity.
Pharmaceutical Commerce
MARCH 4, 2024
Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
328 
Let's personalize your content